Hub-and-spoke telemedicine case conferencing — bringing multidisciplinary rare disease expertise to patients who can't travel to reach it
Roughly 300 million people worldwide live with one of over 7,000 identified rare diseases, yet the clinicians who deeply understand any single rare condition are typically concentrated in a handful of academic medical centers. For a family in a rural town, reaching that expertise historically meant plane tickets, hotel stays, months-long waitlists, and lost wages — a burden that delays diagnosis for years and, for some progressive conditions, costs irreplaceable time.
Deep expertise in any single rare disease is inherently scarce — a condition affecting 1 in 100,000 people means even a busy academic center may see only a handful of cases per year. This concentrates true expertise into a small number of "centers of excellence," typically located in major metropolitan research hospitals.
For patients outside these hubs — and that is the overwhelming majority — accessing that expertise has traditionally required physical travel: multi-day trips, unpaid leave, childcare arrangements, and often a multi-month waitlist just to secure the appointment. For families already exhausted by a diagnostic odyssey, this logistical burden compounds the medical one.
Studies of rare disease referral networks show that patients living more than 100 miles from an academic medical center wait, on average, over twice as long to see the specialist who can make their diagnosis compared to patients living nearby.
The telemedicine expert panel model begins locally: the referring physician and patient assemble everything a distant expert would need — clinical history and exam findings, laboratory and imaging studies, prior specialist notes, and increasingly, genetic or genomic test results (exome or genome sequencing, gene panels).
This packet is transmitted securely to a central telehealth hub — often a university hospital or a disease-specific foundation coordinating center — which triages the case, confirms it fits the panel's scope, and schedules it for a future case conference. Because the packet travels electronically rather than the patient traveling physically, the time-to-first-expert-input drops from months to weeks.
A community physician may see a single case of a given rare disease once or twice in an entire career — there is simply no way to build pattern recognition at that frequency. This is not a failure of the local physician; it reflects the statistical reality of rare disease prevalence.
The expert panel model does not replace the local physician — it augments them. The referring doctor remains the case owner and the person who knows the patient, while the panel supplies the depth of sub-specialty pattern recognition that no single generalist, however skilled, could be expected to hold for thousands of distinct rare conditions.
The dominant architecture for scaling scarce expertise is "hub-and-spoke" telemedicine, popularized by Project ECHO (Extension for Community Healthcare Outcomes), founded at the University of New Mexico in 2003. Instead of moving patients to specialists, hub-and-spoke moves specialist knowledge to patients — a virtual hub of experts connects with many geographically dispersed "spoke" sites and referring clinicians via videoconference.
Project ECHO's original insight was deceptively simple: rather than a one-off consult, build a recurring virtual clinic where a hub team of specialists meets regularly with community providers to co-manage complex cases, teaching as they go. The model has since been adapted widely for rare disease case conferencing — academic rare disease centers now run recurring "virtual tumor board"-style panels where any registered referring physician can submit a case for multidisciplinary review.
Unlike a single specialist e-consult, the panel format deliberately assembles multiple sub-specialties in the same virtual room at the same time — because many rare diseases present with overlapping, multi-system features that no single discipline can fully interpret alone.
A typical rare disease telemedicine panel might include a clinical geneticist, a neurologist, an immunologist, a metabolic disease specialist, and additional sub-specialists relevant to the presenting features — pulmonology, cardiology, ophthalmology, dermatology — drawn from different institutions and often different states or countries.
Each expert joins from their own site using standard videoconferencing, connecting into a shared session hosted by the hub coordinator. The hub is responsible for scheduling, case triage, secure data sharing under patient privacy regulations, and — critically — synthesizing the panel's discussion into a single written recommendation afterward.
Larger panels bring broader diagnostic coverage, but coordination cost rises with panel size — more voices means more scheduling friction and longer discussions before a recommendation converges, which is why most functioning panels settle around 5–15 members.
Hub-and-spoke telemedicine still runs into real-world constraints. Medical licensure is typically state- or country-specific, so a specialist advising on a case in another jurisdiction may need special telehealth licensure exemptions, interstate compacts, or must formally act only in an advisory capacity to the referring physician of record, who remains legally responsible for care.
Reimbursement for panel-based "curbside" consultation has also lagged behind traditional face-to-face billing codes, historically making these programs dependent on grant funding, academic mission budgets, or foundation support rather than routine clinical revenue — though telehealth-specific billing codes have expanded substantially since 2020.
With the panel convened, the case is presented — typically by the referring physician or a hub case coordinator — walking through history, exam findings, labs, imaging, and genetic results. As the presentation unfolds, each specialist begins forming a differential diagnosis through the lens of their own discipline, then voices it for the group.
Most panels follow a consistent structure to keep discussion efficient: chief complaint and history of present illness, developmental/family history, physical exam findings (often supported by patient photos or video clips shared with consent), relevant labs and imaging, and any genetic testing performed to date — including variants of uncertain significance that may need reinterpretation by a specialist familiar with the specific gene.
Because many rare diseases are multi-system, the presentation deliberately avoids framing the case around a single organ system, allowing each specialist to notice the features most relevant to their own field.
Each panelist typically forms an initial impression somewhat independently before the group discussion converges — a geneticist may focus on inheritance pattern and candidate genes, a neurologist on the pattern of weakness or the electrophysiology findings, an immunologist on recurrent infection or autoinflammatory clues.
This parallel, multi-lens generation of hypotheses is the central value proposition of the panel format over a single specialist e-consult: overlapping, multi-system rare diseases are exactly the cases where one discipline's blind spot is another's pattern-recognition strength.
A single specialist reviewing a complex multi-system case in isolation may recognize the features most relevant to their own field and miss cross-cutting clues entirely outside it — the panel format exists specifically to counter this blind spot.
A frequently underappreciated benefit of case-based panels is education: the referring physician who presents and defends their case, and watches specialists reason through it live, absorbs diagnostic pattern recognition they can apply to future patients — even ones never formally referred to the panel. Project ECHO's founding thesis was explicitly this "force multiplier" effect: train the community, don't just treat the patient in front of you.
Over time, physicians who regularly participate in panels report increased confidence managing complex cases independently, gradually reducing the volume of routine cases that need full panel review and freeing panel time for the genuinely novel presentations.
Once every specialist has voiced a differential, the panel enters the deliberative phase: hypotheses are debated, tested against the available evidence, and weighted by how well each explains the full constellation of findings. Some candidate diagnoses are ruled out quickly; others survive scrutiny and rise in the ranking. The output is not always a single certain diagnosis — often it is a ranked, actionable differential with a concrete next-step recommendation for each possibility.
Consensus building is rarely a single vote — it is an iterative process of specialists challenging and refining each other's hypotheses in real time. A candidate diagnosis that seems compelling to one specialist may be quickly eliminated when another points out an incompatible lab value or exam finding; conversely, a weak initial hypothesis can gain support once a specialist supplies context others lacked.
Some panels use lightweight structured methods — informal polling, ranked-choice discussion, or a coordinator tallying support — to keep the conversation converging rather than circling indefinitely, especially as panel size grows and more voices need to be reconciled.
Not every case resolves to a confident diagnosis in a single session, and that is treated as a legitimate outcome rather than a failure. Case complexity — atypical presentations, incomplete testing, or genuinely novel phenotypes — can mean the most useful thing a panel can deliver is a prioritized workup plan: which additional tests would most efficiently discriminate between the surviving candidate diagnoses.
These cases are frequently scheduled for a follow-up panel review once new data (a repeat genetic test, a specific antibody panel, a muscle biopsy) returns, rather than leaving the referring physician without a path forward.
Panel size creates a real tradeoff. A larger panel covers more sub-specialties and is less likely to miss a relevant diagnostic angle — but each additional expert adds a voice that must be heard, a hypothesis that must be reconciled, and scheduling complexity that must be managed. Coordinators of long-running rare disease panels generally find that somewhere around 8–12 members balances diagnostic breadth against a discussion that can still converge within a single session.
Beyond roughly a dozen active panelists, discussion time grows faster than diagnostic yield — most established rare disease panels cap membership and instead rotate specialists in based on the specific features of each submitted case.
The panel's output only creates value once it reaches back to the people who can act on it: the referring physician and the patient. A written summary — the consensus differential, the recommended next steps, and any suggested medication, monitoring, or referral changes — is sent back down the spokes of the network, translating expert-level reasoning into a concrete local care plan the community physician can execute.
The written recommendation is deliberately actionable rather than purely academic: specific tests to order, medications to start or adjust, red-flag symptoms that should trigger urgent re-referral, and — where relevant — which additional specialist involvement is genuinely needed in person versus what the local physician can manage directly with panel guidance.
Because the referring physician remains the clinician of record throughout, the recommendation is framed as decision support, preserving the local relationship and continuity of care that matters enormously for patients managing a lifelong rare condition.
The evidence base for hub-and-spoke telemedicine panels draws heavily from Project ECHO's now 15+ year track record across hepatitis C, chronic pain, and increasingly rare disease and genetics applications: participating community providers show measurable gains in diagnostic and management confidence, and patient outcomes in ECHO-supported conditions have in several studies approached those achieved at the academic hub itself — without the patient ever needing to travel there.
For rare diseases specifically, published case series from academic genetics telemedicine panels report meaningful reductions in time-to-diagnosis and high rates of clinically actionable recommendations, though rigorous large-scale outcome trials remain an active area of ongoing research.
The core promise of the model is democratizing access: a patient's zip code should influence how quickly they get to a diagnosis far less than it does today, and every case successfully resolved without travel is capacity freed for the next family who needs the same panel.
The model is not a replacement for in-person specialty care in every case — some diagnoses ultimately require an in-person exam, a procedure, or a biopsy that cannot happen virtually, and the panel's recommendation quality is only as good as the completeness and accuracy of the case data submitted upfront. Poor-quality imaging, incomplete history, or a genetic test that was never actually ordered can all limit what even the best panel can conclude remotely.
Licensure boundaries, reimbursement gaps, and the reality that panels are often volunteer or grant-supported rather than a stable clinical service line remain open challenges to scaling the model to meet the full scope of global rare disease need.